NSE மற்றும் BSE-யின் ஒவ்வொரு கார்ப்பரேட் அறிவிப்பும், AI-யால் சில நிமிடங்களில் படிக்கப்பட்டு விளக்கப்படுகிறது — தாக்கம், முக்கிய புள்ளிவிவரங்கள், குறுகிய/நீண்டகாலப் பார்வை, கவனிக்க வேண்டியவை.
நேரலைசமீபத்திய அறிவிப்பு: 2026-08-14 17:22இன்று 0 பகுப்பாய்வு செய்யப்பட்டது
குறிப்பு: இவை NSE பொது அறிக்கைகளின் AI-உருவாக்கிய, கல்வி நோக்கச் சுருக்கங்கள் — ஒவ்வொரு ஆவணத்தையும் ஆதாரமாகக் கொண்டவை, ஆனால் முதலீட்டு ஆலோசனை அல்ல, மேலும் முழுமையற்றதாகவும் இருக்கலாம். அசல் அறிக்கையுடன் சரிபார்க்கவும், செயல்படுவதற்கு முன் SEBI-பதிவு பெற்ற முதலீட்டு ஆலோசகரை அணுகவும்.
Ajooni Biotech Q1 Revenue Surges 103% YoY to Rs 63.49 Cr; PAT Drops 45% to Rs 0.43 Cr
Ajooni Biotech reported standalone revenue from operations of Rs 63.49 Cr for the quarter ended June 30, 2026, representing a 103% YoY growth compared to Rs 31.27 Cr in Q1 FY26. However, net profit declined 44.7% YoY to Rs 0.43 Cr (vs Rs 0.78 Cr in Q1 FY26) due to raw material costs jumping to Rs 54.55 Cr and rising finance costs of Rs 0.48 Cr. Profit before tax contracted to Rs 0.65 Cr from Rs 1.03 Cr in the year-ago period. Current borrowings rose sharply to Rs 25.50 Cr as of June 30, 2026, up from Rs 16.22 Cr as of March 31, 2026.
உச்சம் நம்பிக்கை
என்ன மாறியதுAjooni Biotech reported Q1 standalone financial results reflecting strong revenue scaling alongside significant net margin contraction.
ஏன் இது முக்கியம்Top-line doubling shows increased volume processing from capacity additions, but elevated input costs and higher leverage are suppressing profitability.
Revenue from operations (Q1): Rs 6,349.07 LakhsNet Profit (Q1): Rs 43.18 LakhsCost of materials consumed: Rs 5,454.86 LakhsFinance costs: Rs 48.21 LakhsCurrent borrowings (as of 30.06.2026): Rs 2,550.27 Lakhs
📅 குறுகிய காலம்Margin compression and doubling of finance costs are likely to dampen sentiment despite top-line growth.
📈 நீண்ட காலம்Long-term re-rating relies on transitioning product mix into 9-10% margin animal feed supplements to build pricing power against input cost fluctuations.
⚠ அபாய எச்சரிக்கைகள்
Severe margin compression from raw material price pressures
Sharp increase in short-term debt and finance costs
Limited pricing power in a fragmented compound feed industry
👀 கவனிக்க வேண்டியவை
Track whether the company can expand higher-margin feed supplements to counter raw material cost inflation and control rising short-term borrowing levels.
Ajooni Biotech has approved the allotment of 90,00,000 equity shares at a price of ₹4.30 per share, aggregating to ₹3.87 crore. The allotment was made via a preferential issue to a single entity, Healthy Biosciences Limited. The issue price of ₹4.30 is notably higher than the current market price of ₹3.80. This capital infusion represents approximately 6.1% of the company's current market capitalization of ₹63 crore.
உச்சம் நம்பிக்கை
என்ன மாறியதுThe company has completed a preferential allotment of 90 lakh shares, resulting in a capital infusion of ₹3.87 crore and a corresponding increase in the total outstanding equity.
ஏன் இது முக்கியம்The fundraise provides immediate liquidity and strengthens the net worth (currently ₹91 Cr). The fact that the allotment happened at a premium to the market price suggests investor confidence in the company's shift toward high-margin feed supplements.
Total Allotment Value: ₹3.87 கோடிIssue Price per Share: ₹4.30Fundraise vs Market Cap: ~6.1%Fundraise vs Net Worth: ~4.2%Number of Shares Allotted: 90,00,000
📅 குறுகிய காலம்The allotment at a premium (₹4.30) relative to the current market price (₹3.80) is likely to be viewed as a positive signal by the market in the short term.
📈 நீண்ட காலம்While the fundraise is relatively small compared to TTM revenue (₹182 Cr), it supports the company's stated goal of strengthening net worth and expanding capacity in the animal nutrition space.
⚠ அபாய எச்சரிக்கைகள்
Equity dilution for existing shareholders
Concentration of new shares with a single investor
👀 கவனிக்க வேண்டியவை
Investors should monitor the utilization of these funds, particularly whether they are deployed toward the company's planned ₹16.5 Cr factory expansion or to reduce the ₹18 Cr debt. Watch for the next shareholding pattern to see the impact on promoter vs. public holding.
90 Lakh Shares Preferential Issue Approved at Rs 4.30 per Share
Ajooni Biotech's shareholders have approved the issuance of 90,00,000 equity shares on a preferential basis at the 16th Annual General Meeting. The issue price of Rs 4.30 per share represents a premium over the current market price of Rs 4.0. This fundraise will inject approximately Rs 3.87 crore into the company, representing about 5.9% of its current market capitalization. The capital is likely intended to support the company's ongoing expansion into high-margin animal feed supplements.
உச்சம் நம்பிக்கை
என்ன மாறியதுThe company has received formal shareholder approval to proceed with a preferential equity issue of 90 lakh shares.
ஏன் இது முக்கியம்This provides a capital cushion to support the company's transition toward specialized feed supplements which offer higher margins (9-10%) compared to standard cattle feed. The issuance at a premium to the market price is generally a positive signal regarding internal valuation.
Shares to be issued: 90,00,000Issue Price: Rs 4.30Estimated Fundraise: Rs 3.87 கோடிFundraise vs Market Cap: ~5.9%Current Market Price: Rs 4.0
📅 குறுகிய காலம்The stock may see positive sentiment due to the preferential issue being priced at a premium to the current market price.
📈 நீண்ட காலம்The capital supports the company's strategy to reach a net worth of Rs 84 Cr and expand capacity, which is critical for achieving its 25-30% growth target.
⚠ அபாய எச்சரிக்கைகள்
Equity dilution of approximately 5-6% for existing shareholders
Utilization of funds depends on timely execution of the new factory project
👀 கவனிக்க வேண்டியவை
Investors should monitor the upcoming disclosure regarding the identity of the allottees (promoters vs. strategic investors) and the specific timeline for the deployment of these funds into the new production facility.
Ajooni Biotech AGM: Shareholders Approve Preferential Issue and Capital Increase
Ajooni Biotech concluded its 16th AGM on July 29, 2026, where shareholders voted on four key resolutions including a preferential issue of equity shares. This capital raise follows a strong FY26 performance where revenue grew ~59% to Rs 182.38 Cr. The company is currently executing a strategic shift toward high-margin (9-10%) feed supplements supported by a new Rs 16.5 Cr factory. Investors should note that while the fundraise supports growth, it will lead to equity dilution in a company with a relatively low promoter holding of 26.9%.
உச்சம் நம்பிக்கை
என்ன மாறியதுThe company has obtained shareholder approval to proceed with a preferential share issuance and an increase in its authorized capital structure.
ஏன் இது முக்கியம்This fundraise is critical for a micro-cap company (Rs 66 Cr market cap) to fund its Rs 16.5 Cr capacity expansion and transition into higher-margin product segments.
FY26 Revenue: Rs 182.38 கோடிசந்தை மதிப்பு: Rs 66 கோடிShareholders as of July 17, 2026: 60,449Planned Capex for New Factory: Rs 16.5 கோடிPromoter Holding: 26.89%
📅 குறுகிய காலம்The stock may see interest as the market anticipates the details of the new investors coming in through the preferential route.
📈 நீண்ட காலம்If the raised capital successfully operationalizes the new facility and shifts the product mix to 9-10% margin supplements, it could structurally re-rate the business.
⚠ அபாய எச்சரிக்கைகள்
Equity dilution from preferential issue
Low promoter holding at 26.89%
Susceptibility to raw material price spikes in maize and mustard
👀 கவனிக்க வேண்டியவை
Watch for the detailed voting results and the specific terms of the preferential issue, including the issue price and the identity of the allottees, to assess dilution impact.
Ajooni Biotech to Raise ₹3.87 Cr via Preferential Issue; Proposes ₹20 Cr Capital Increase
Ajooni Biotech has scheduled its 16th Annual General Meeting for July 29, 2026, to seek approval for a preferential allotment of 90 lakh shares to its promoter, Healthy Biosciences Limited. The issue is priced at ₹4.30 per share, totaling ₹3.87 Cr, which represents approximately 2.1% of the company's TTM revenue. Additionally, the company proposes increasing its authorized share capital by ₹20 Cr to ₹70 Cr, providing headroom for future equity expansion. This move aligns with the company's stated strategy to strengthen its net worth and fund its shift toward high-margin feed supplements.
உச்சம் நம்பிக்கை
என்ன மாறியதுThe company is initiating a promoter-led fund infusion and expanding its authorized capital limit to facilitate future growth and equity requirements.
ஏன் இது முக்கியம்The promoter infusion of ₹3.87 Cr, while small relative to revenue, signals confidence and provides liquidity for the company's transition into specialized feed supplements with 9-10% margins.
Preferential Issue Size: ₹3.87 கோடிIssue Price per Share: ₹4.30Authorized Capital Increase: ₹20 கோடிIssue Size vs TTM Revenue: ~2.1%Issue Size vs Net Worth: ~4.25%AGM Date: ஜூலை 29, 2026
📅 குறுகிய காலம்The stock may see neutral to slightly positive sentiment as the market processes the promoter's commitment at a specific price point.
📈 நீண்ட காலம்The increase in authorized capital and promoter support are structural steps toward the company's goal of scaling its animal nutrition business and improving OPM from the current 3.4%.
⚠ அபாய எச்சரிக்கைகள்
Minority shareholder dilution
Promoter holding is relatively low at 26.9%
👀 கவனிக்க வேண்டியவை
Monitor the shareholder vote on July 29, 2026, and subsequent allotment timeline to see if the funds are deployed toward the ₹16.5 Cr factory expansion slated for completion in FY26.
📊 கடந்த 7 நாட்கள் — உணர்வு அடிப்படையில் பகுப்பாய்வு செய்யப்பட்ட அறிவிப்புகள்
₹3.87 Cr Preferential Issue to Promoters; Stake to Increase to 30.53%
Ajooni Biotech's board has approved a preferential issue of 90 lakh equity shares to a promoter group entity, Healthy Biosciences Limited, at a price of ₹4.30 per share. This ₹3.87 crore infusion will increase the promoter holding from 26.89% to 30.53%, signaling increased promoter commitment. To facilitate this and future requirements, the company is also increasing its authorized share capital from ₹50 crore to ₹70 crore. The proposal is subject to shareholder approval at the upcoming AGM on July 29, 2026.
உச்சம் நம்பிக்கை
என்ன மாறியதுThe company is raising equity capital specifically from its promoters, which will increase the total number of outstanding shares to 18.12 crore.
ஏன் இது முக்கியம்While the fundraise is small (approx. 2.1% of TTM revenue), the increase in promoter stake from a relatively low level (26.89%) is a positive signal of management's confidence in the company's shift toward high-margin feed supplements.
Total Issue Value: ₹3.87 கோடிIssue Price: ₹4.30Post-Issue Promoter Holding: 30.53%Fundraise vs TTM Revenue: ~2.1%New Authorized Capital: ₹70 கோடி
📅 குறுகிய காலம்The market may view the promoter's decision to increase their stake at ₹4.30 as a floor for the stock price in the near term.
📈 நீண்ட காலம்The capital infusion supports the company's stated strategy to strengthen its net worth and transition into specialized animal nutrition, though the small scale of this specific raise suggests it is part of a larger funding mix.
⚠ அபாய எச்சரிக்கைகள்
Small fundraise magnitude relative to expansion needs
High public shareholding (69.47%) even after this issue
Deferred decision on MD remuneration suggests ongoing internal reviews
👀 கவனிக்க வேண்டியவை
Investors should monitor the shareholder voting results from the AGM on July 29, 2026, and track the progress of the ₹16.5 Cr factory expansion previously slated for completion.
Ajooni Biotech FY26 Revenue Jumps 59% to ₹182.38 Cr; Annual Net Profit Rises 28%
Ajooni Biotech Limited reported a robust performance for the fiscal year ended March 31, 2026, with annual revenue from operations surging 59% to ₹18,237.81 lakhs. Full-year net profit grew by 28% to ₹432.19 lakhs compared to ₹337.20 lakhs in the previous year. However, the fourth quarter (Q4 FY26) showed margin pressure, with net profit declining to ₹94.72 lakhs from ₹154.38 lakhs YoY, despite a doubling of quarterly revenue. The company also saw a significant increase in current borrowings to ₹1,622.28 lakhs.
முக்கிய அம்சங்கள்
Annual revenue from operations increased by 59.01% YoY to ₹18,237.81 lakhs.Full-year net profit after tax rose 28.17% to ₹432.19 lakhs.Q4 FY26 revenue doubled to ₹6,062.21 lakhs compared to ₹2,927.44 lakhs in Q4 FY25.Annual Earnings Per Share (EPS) improved to ₹0.25 from ₹0.20 YoY.Current borrowings increased significantly to ₹1,622.28 lakhs from zero in the previous fiscal year end.
👀 கவனிக்க வேண்டியவை
Investors should appreciate the strong top-line growth but remain cautious about the declining quarterly margins and the sharp rise in short-term debt. Monitor the company's ability to pass on rising material costs to maintain profitability.
Ajooni Biotech Secures Record ₹47.52 Cr Order; Triples Capacity to 1.8 Lakh MT
Ajooni Biotech has secured its largest-ever single order worth ₹47.52 crores for cattle feed from an existing customer, representing a significant portion of its current revenue. The company also announced the commissioning of its new Khanna plant, which increases total annual production capacity from 60,000 MT to 180,000 MT. For 9M FY26, the company reported a revenue of ₹122.87 crores and a PAT of ₹3.37 crores. Furthermore, the board is evaluating a potential merger with Healthy Biosciences Limited to drive inorganic growth.
முக்கிய அம்சங்கள்
Received record-breaking order worth ₹47.52 crores for scientifically formulated cattle feedCommissioned new facility in Khanna, Punjab, tripling total annual capacity to 1,80,000 MTReported 9M FY26 financial performance with ₹122.87 crore revenue and ₹3.37 crore PATBoard is actively discussing the merger/amalgamation of Healthy Biosciences Limited with AjooniNew plant technology expected to significantly reduce production costs and improve margins
👀 கவனிக்க வேண்டியவை
Investors should view the massive capacity expansion and record order book as strong growth catalysts for FY27. Monitor the progress of the proposed merger with Healthy Biosciences for potential synergy benefits.
Ajooni Biotech Secures Major Cattle Feed Order Worth Rs. 47.52 Crores
Ajooni Biotech Limited has successfully secured a significant order valued at Rs. 47.52 crores for the supply of its scientifically formulated cattle feed. This order from a valued customer highlights the company's strengthening market position in the animal nutrition segment. The contract underscores growing demand and customer confidence in the company's product quality. This development is expected to provide a substantial boost to the company's revenue and operational scale in the near term.
முக்கிய அம்சங்கள்
Received a new supply order worth Rs. 47.52 crores.Order pertains to the supply of scientifically formulated cattle feed.Strengthens the company's footprint in the animal nutrition industry.Reflects robust demand and customer trust in product excellence.
👀 கவனிக்க வேண்டியவை
Investors should view this as a positive growth indicator and monitor the company's ability to execute this order efficiently. Watch for the impact on upcoming quarterly revenue and profit margins.
Ajooni Biotech Q3 Net Profit Jumps 125% YoY to ₹1.65 Cr; Merger Proposal Deferred
Ajooni Biotech reported a strong financial performance for the quarter ended December 31, 2025, with revenue from operations growing 72.6% YoY to ₹58.75 crore. Net profit for the quarter surged by 125.7% YoY to ₹1.65 crore, up from ₹0.73 crore in the same period last year. For the nine-month period, the company has already matched its previous full-year profit, reaching ₹3.37 crore. While the board discussed a merger with Healthy Biosciences Limited, the decision has been deferred for further evaluation, which remains a key watchpoint for future growth.
முக்கிய அம்சங்கள்
Revenue from operations grew 72.6% YoY to ₹5,875.33 Lakhs in Q3 FY26.Net profit for the quarter increased 125.7% YoY to ₹164.80 Lakhs.9-month (Apr-Dec 2025) revenue reached ₹12,175.61 Lakhs vs ₹8,541.75 Lakhs YoY.Earnings Per Share (EPS) for the quarter improved to ₹0.10 from ₹0.04 YoY.Board deferred the merger proposal of Healthy Biosciences Limited pending further internal evaluation.
👀 கவனிக்க வேண்டியவை
Investors should take note of the significant top-line and bottom-line expansion; however, they should monitor updates regarding the deferred merger which could impact long-term valuation.
Ajooni Biotech Commences Production & Receives Orders Worth ₹27 Crores
Ajooni Biotech Limited has announced the commencement of commercial production at its newly installed manufacturing facilities in Khanna, Punjab. This expansion is expected to significantly contribute to the company's revenue and market presence. Furthermore, the company has secured new orders for cattle feed valued at ₹27 Crores, demonstrating strong customer trust in both domestic and export markets. Investors should monitor the impact of this increased production capacity and order fulfillment on the company's future financial performance.
முக்கிய அம்சங்கள்
Commercial production commenced at newly installed manufacturing facilities.Received new orders for cattle feed valued at ₹27 Crores.New facility located in Khanna, Punjab.
👀 கவனிக்க வேண்டியவை
Investors should closely monitor Ajooni Biotech's revenue growth and profitability in upcoming quarters to assess the impact of the new production facility and order book. Review the company's quarterly reports for updates on capacity utilization and order execution.
⚠️இந்தத் தளம் எவ்வாறு உருவாக்கப்படுகிறது: சந்தைத் தரவுப் பக்கங்கள் NSE/BSE வெளியீடுகள் மற்றும் நிறுவனங்களின் தாக்கல்களிலிருந்து தானாகக் கணக்கிடப்படுகின்றன; செய்திக் கட்டுரைகளும் அறிவிப்புப் பகுப்பாய்வுகளும் AI உதவியுடன் எழுதப்படுகின்றன, மனித மேற்பார்வையுடன்: AI உருவாக்குவதை எங்கள் ஆசிரியர்கள் மதிப்பாய்வு செய்கின்றனர். இரண்டிலும் பிழைகள் இருக்கலாம். எந்தவொரு முதலீட்டு முடிவுக்கு முன்பும் அசல் மூலங்களில் சரிபார்க்கவும். முதலீட்டு ஆலோசனை அல்ல; Flash Finance SEBI-பதிவு பெற்றது அல்ல. நாங்கள் AI-ஐ எவ்வாறு பயன்படுத்துகிறோம்
🎁 ஆரம்பகால ஆதரவாளர்களுக்கு மட்டும் · குறுகிய கால சலுகை
எங்கள் AI பங்குச் சந்தை பகுப்பாய்வு: டெலிகிராம், வாட்ஸ்அப்பில் இலவசம்
⚡ 3500+ நிறுவனங்களை நாங்கள் உடனுக்குடன் கண்காணிக்கிறோம். NSE-யில் ஒரு நிறுவன அறிவிப்பு வெளியானதுமே, எங்கள் AI அதைப் படித்து, சுருக்கி, அதன் தாக்கத்தைச் சில நொடிகளில் உங்களுக்குச் சொல்கிறது.
இதுபோன்ற AI பகுப்பாய்வுக்குக் கட்டணத் தளங்கள் ஆண்டுக்கு ₹1,00,000-க்கும் மேல் வசூலிக்கின்றன. எங்கள் சேனல்களில் இது இலவசம்.
